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ABSTRACT
Targeted cell- or region-specific gene recombination is widely used in
the functional analysis of genes implicated in development and
disease. In the brain, targeted gene recombination has become a
mainstream approach to study neurodegeneration or tumorigenesis.
The use of the Cre-loxP system to study tumorigenesis in the adult
central nervous system (CNS) can be limited, when the promoter
(such as GFAP) is also transiently expressed during development,
which can result in the recombination of progenies of different
lineages. Engineering of transgenic mice expressing Cre
recombinase fused to a mutant of the human oestrogen receptor
(ER) allows the circumvention of transient developmental Cre
expression by inducing recombination in the adult organism. The
recombination of loxP sequences occurs only in the presence of
tamoxifen. Systemic administration of tamoxifen can, however,
exhibit toxicity and might also recombine unwanted cell populations
if the promoter drivingCre expression is active at the time of tamoxifen
administration. Here, we report that a single site-specific injection
of an active derivative of tamoxifen successfully activates Cre
recombinase and selectively recombines tumour suppressor genes
in neural progenitor cells of the subventricular zone in mice, and we
demonstrate its application in a model for the generation of intrinsic
brain tumours.
KEY WORDS: Brain tumour, Cre recombination, Endoxifen,
loxP system, Tamoxifen
INTRODUCTION
The adult central nervous system (CNS) contains several stem cell
compartments, which have been studied extensively. One of the
major regions in which new neurons and glial cells are generated is a
germinal niche adjacent to the walls of the lateral ventricles in the
adult brain (Doetsch, 2003; Doetsch and Alvarez-Buylla, 1996;
Doetsch et al., 1999, 1997). The introduction of oncogenic
mutations into this cell population has been used to model brain
tumours, for example by Cre-mediated recombination of tumour
suppressor genes such as Pten, p53, Rb or Nf1 (Chow et al., 2011;
Jacques et al., 2010; Zheng et al., 2008; Zhu et al., 2005). Although
the Cre-lox system can avoid embryonic lethality hampering many
classical gene knockout models, there are still limitations, as, for
example, seen in transgenic mice expressing Cre recombinase under
the control of the glial fibrillary acidic protein (GFAP) promoter.
GFAP expression is not limited to astrocytes or to mature stem cells
but is also transiently expressed in neural precursors during CNS
development, resulting in a recombination of all progenies of cells
that expressed Cre during development (Kwon et al., 2001;
Lewandoski, 2001; Marino et al., 2002, 2000; Zheng et al., 2008;
Zhuo et al., 2001). This can be circumvented by several approaches,
for example by direct injection of a viral vector expressing Cre
recombinase (Ahmed et al., 2004), which can be refined by a tissue-
specific promoter such as GFAP (Jacques et al., 2010), or by using
transgenic mice expressing Cre under the control of a tamoxifen-
inducible promoter. Such mice express Cre recombinase fused to a
mutated form of the human oestrogen receptor (ER), which results
in the expression of the fusion protein CreERT2. In the inactive
form, CreERT2 is quenched by heat shock 90 protein (Hsp90) and
resides within the cytoplasm. Upon binding of the oestrogen
analogue tamoxifen, CreERT2 is released from Hsp90 and is
translocated into the nucleus, where it can catalyse the
recombination of floxed DNA sequences. The generation of
CreERT2 transgenic mice allows the activation of Cre expression
in a time-controlled fashion (Chow et al., 2008; Metzger and
Chambon, 2001; Mori et al., 2006). Tamoxifen can induce
Cre activity only after it is converted into its active metabolites,
such as 4-hydroxytamoxifen (4-OH-TAM) or 4-hydroxy-N-
desmethyltamoxifen (endoxifen) (Hayashi and McMahon, 2002).
Topical application of tamoxifen to recombine CreERT2-driven
promoters has been previously used for studies in skin biology. The
limitations of some conditional knockout models of skin diseases
are similar to those in the CNS, where complete and tissue-specific
Cre-mediated gene knockout results in embryonic or early perinatal
death, precluding the analysis of gene function in different cell types
and in the regulation of skin homeostasis (Gunschmann et al., 2014;
Lewandoski, 2001). In analogy to the more established trans-
epidermal topical application of tamoxifen for Cre-mediated gene
recombination, we set out to establish (i) whether injection of active
metabolites into the cerebral ventricles can directly activate Cre
expression in stem cells, thus targeting a regionally and spatially
defined, specific population of cells and (ii) whether the regional
expression in a selected cell population leads to the generation of
tumours and how they might compare to tumours induced by
recombination due to Cre-expressing adenovirus (Adeno-Cre) or
Adeno-GFAP-Cre (Henriquez et al., 2013; Jacques et al., 2010). To
this end, we used mice expressing CreERT2 under control of the
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(Mori et al., 2006), which is expressed in a range of glial cells
including B-type stem cells (Doetsch, 2003; Doetsch and Alvarez-
Buylla, 1996; Doetsch et al., 1999, 1997). By crossing these mice
with conditional knockout mice carrying floxed alleles of the
tumour suppressor genes p53 ( p53loxP/loxP) and Pten (PtenloxP/loxP),
we explored whether this highly selective and regionally confined
targeting would modify the phenotype of tumours arising from the
subventricular zone (SVZ) stem/progenitor cells.
RESULTS
Optimisation of tamoxifen dosage for intracerebral injection
To establish an optimal concentration of 4-OH-TAM or endoxifen to
elicit Cre expression with minimal toxicity, we sought to establish
the following parameters: (i) optimal concentration for gene
recombination, (ii) minimal toxicity and (iii) the optimal volume and
carrier (DMSOor ethanol). Table 1 shows the volumes, concentrations
and resulting amounts of drug injected intraventricularly. Because only
in vitro data were available for the concentrations of 4-OH-TAM or
endoxifen,we first set out to determine the volumes and concentrations
of intraventricularly injected endoxifen and 4-OH-TAM required for
in vivo cell recombination and to determine potential toxicity. This
experiment would also inform about the occurrence of possible toxic
side effects at higher concentrations.
Although a 0.1 µM concentration of 4-OH-TAM is effective
in cell culture experiments (Wassarman and Soriano, 2010), we
started the dosage of intraventricular (ICV) injections at an arbitrary
concentration of 1 mM dissolved in 2% ethanol/PBS (5 µl) to inject
into the ventricles of ROSA26loxP/loxP mice, which we considered to
be a compromise between minimal side effects and sufficient
concentration at the ventricular wall in the circulating cerebrospinal
fluid. However, recombination analysis of brains 1 week after
injection showed no β-galactosidase activity and thus no
recombination. Next, we injected 5 µl of 4-OH-TAM at a
concentration of 2 mM dissolved in 4% ethanol into the
hippocampus, which also contains GLAST-expressing cells. We
regarded 4% ethanol as the maximum tolerable concentration in the
brain. After a 1-week incubation, the brains were assayed for
β-galactosidase activity and now showed recombination in the
cortex, the hippocampus and the third ventricle, demonstrating that
an active tamoxifen metabolite is capable of eliciting recombination
in the context of a CreERT2 transgenic system. However, the
relatively ineffective recombination prompted us to further explore
endoxifen (4-hydroxy-N-desmethyl-tamoxifen) (Ahmad et al.,
2010; Johnson et al., 2004; Jordan, 2007; Stearns et al., 2003), an
alternative derivative for which tamoxifen is metabolised in the liver
and has so far not been used before for Cre-mediated induction of
the ERT2 system in vivo. We used concentrations of 2.5, 5, 10, 12.5
and 25 mM, dissolved in 10, 20, 40, 50 and 100% DMSO,
respectively, corresponding to a drug dose of 12.5, 25, 50, 62.5 and
125 nmol (Table 1). No neurological signs of toxicity were
observed at the 2.5 and 5 mM concentrations, whereas single-
occurrence neurological signs suggestive of drug toxicity doses
were observed at the 10 and 12.5 mM concentrations and more
frequent neurological signs of toxicity at the 25 mM concentration
were noted. No neurotoxicity was observed in mice that received up
to 100% DMSO (vehicle) only, as reported previously (Blevins
et al., 2002; Schick et al., 1990). To confirm the absence
of morphologically detectable cellular damage, we assessed
DMSO toxicity systematically by injecting 5 µl of PBS, 50%
DMSO or 100% DMSO into the ventricle of GLAST::CreERT2;
ROSA26loxP/loxP mice. All mice tested – the PBS-injected mice
and the two groups of DMSO-injected mice – showed single
cells positive for cleaved caspase3 (Fig. 1A-F) in the SVZ.
There was no statistically significant increase of caspase in the
DMSO-injected groups, which showed, as did controls, 0 or 1
caspase-3 positive cells in the SVZ. However, DMSO injection
Table 1. Summary of tested intracranial injections with 4-OH-TAM and endoxifen
Substance Region injected Conc. (mM) Volume (µl) Amount (nmol) Diluent/solvent Comments
4-OH-TAM Lateral ventricle 1 2 2 2% EtOH No recombination
Lateral ventricle 2 3 6 4% EtOH No recombination
Lateral ventricle 2 5 10 4% EtOH No recombination
Hippocampus 2 3 6 4% EtOH Parenchymal recombination
Hippocampus 2 4 8 4% EtOH Parenchymal recombination
Hippocampus 2 5 10 4% EtOH Parenchymal recombination
Endoxifen Lateral ventricle 2.5 5 12.5 10% DMSO Well tolerated
Lateral ventricle 5 5 25 20% DMSO Well tolerated
Lateral ventricle 10 5 50 40% DMSO Occasionally unwell, no
termination required
Lateral ventricle 12.5 5 62.5 50% DMSO Occasional toxicity,
termination required
Lateral ventricle 25 5 125 100% DMSO Frequent toxicity, termination
required
DMSO Lateral ventricle 0 5 0 100% DMSO
ipsilateral
Caspase: 1-2 pos. cells in
SVZ
Lateral ventricle 0 5 0 100% DMSO
contralateral
Caspase: 0-1 pos. cell in SVZ
Lateral ventricle 0 5 0 50% DMSO
ipsilateral
Caspase: 0-1 pos. cell in SVZ
Lateral ventricle 0 5 0 50% DMSO
contralateral
Caspase: 0-1 pos. cell in SVZ
Lateral ventricle 0 5 0 PBS ipsilateral Caspase: 0-1 pos. cell in SVZ
Lateral ventricle 0 5 0 PBS contralateral Caspase: 0-1 pos. cell in SVZ
4-OH-TAM was tested in SVZ and hippocampus and the stock solution was diluted in ethanol, whereas endoxifen, diluted in DMSO, was tested exclusively
intraventricularly to target the SVZ. 4-OH-TAM was ineffective in eliciting recombination and was therefore not further pursued. DMSO toxicity was assessed
9 days after intraventricular injection. Assessment was done on the SVZ ipsilateral and contralateral to the injection site. Cleaved caspase-3-positive (pos.) cells
were determined in the SVZ ipsilateral and contralateral to the injection (see also Fig. 1).
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resulted in a mild increase of activated microglia (Fig. 1G-L) and
astrocytes (Fig. 1M-R) on the side of the injection (microglia in
Fig. 1J,P, and astrocytes in Fig. 1L,R).
Endoxifen-mediated CreERT2 recombination occurs in a
dose-dependent fashion
Recombination occurred at all concentrations of endoxifen tested, in
a dose-dependent manner, as visualised by X-Gal staining in the
SVZ (Fig. 2). At high endoxifen concentrations (12.5 mM and
25 mM), recombination took place in SVZ cells and rarely in
adjacent, likely differentiated, astrocytes. At lower concentrations,
recombined cells were restricted to the SVZ (Fig. 2A-D), and were
also less frequent, thus reducing the number of potentially
recombined, tumour-generating, cells in future experimental
settings. Brains of non-injected or DMSO-injected GLAST::
CreERT2;ROSA26loxP/loxP showed no recombination and thus no
expression of β-galactosidase. Endoxifen-mediated Cre activation
results in recombination of both alleles, as assessed by
recombination PCR (see later) or by detection of pAkt, which
becomes phosphorylated and accumulates in tumour cells in which
PTEN protein expression is abolished (Groszer et al., 2001; Marino
et al., 2002; also discussed later).
Characterisation of cell types recombined by endoxifen in
the brain of GLAST::CreERT2;ROSA26loxP/loxPmice
Within the SVZ, GLAST is not expressed by B-type stem
cells (Mori et al., 2006). We compared the endoxifen-induced
Cre-mediated recombination with that of our established, and well-
characterised, method of Adeno-Cre-mediated recombination,
which served as control (Jacques et al., 2010). Immunohistochemical
detection of β-galactosidase, a marker of recombination in
ROSA26loxP/loxP reporter mice, shows widespread expression in
the ventricular system, including the lateral (Fig. 3A,B,D,E) and the
third (Fig. 3G,H) ventricles in both recombination methods, but not
in the CNS parenchyma subjacent to the SVZ. Choroid plexus
epithelial cells were recombined byAdeno-Cre (Fig. 3K), but not by
the endoxifen (Fig. 3J) system because GLAST is not expressed by
choroid plexus epithelium, confirming the specificity of the
approach. As expected, intraperitoneal injection of tamoxifen base
resulted in a widespread recombination in glial cells in the
brain, including the SVZ (Fig. 3M-O), as previously reported
(Mori et al., 2006), and controls were non-recombined throughout
(Fig. 3C,F,I,L).
Double-labelling immunofluorescence was used to colocalise
the stem/progenitor marker GFAP with Cre-expressing cells
(Fig. 4A-C) and the resulting recombination was assayed by
detection of β-galactosidase (Fig. 4D,E,G,H). We found that
Fig. 1. Cellular reaction to intraventricular DMSO injection. The cerebral
ventricles were injected with 5 µl PBS (A,B,G,H,M,N), 50% DMSO in PBS
(C,D,I,J,O,P) or 100% DMSO (E,F,K,L,Q,R). (A-F) Immunohistochemical
staining for cleaved caspase 3 to detect apoptotic cells/nuclei shows occasional
positive cells in controls and both DMSO groups. Arrowheads point to single
positive cells in the SVZ, shown at higher magnification in A'-F'. Single cells are
detected bilaterally in the SVZ. The PBS group shows a single cell contralateral
to the injection (A), and there is a single cell in the contralateral wall in the 50%
DMSO-injected brain, and a single cell on the contralateral side and two cells on
the ipsilateral side of the 100% DMSO-injected brain. (G-L) Mice injected with
DMSO show a mild microglial reaction on the injected side (J,L). (M-R) This is
also associatedwith amild tomoderate astrocytic gliosis, which is present on the
side of injection (P,R). Scale bar: 25 µm for A′-F′, and 100 µm in all other panels.
Fig. 2. β-galactosidase activity following
endoxifen-mediated Cre-induced recombination
in the SVZ ofGLAST::CreERT2;ROSA26loxP/loxP
reportermice.Coronal sections, developed for X-Gal
enzymatic colourimetric reaction (A-G) and
subsequent counterstaining with Nuclear Fast Red
(H-N). (A,H) PBS-injected controls show no
recombination. Arrowheads point to the lateral wall of
the SVZ. d, dorsal; l, lateral; m, medial; v, ventral.
(B-F,I-M) The number of X-Gal-positive cells in the
SVZ increased with the concentration of endoxifen.
(G,N) Adeno-Cre-mediated recombination shows a
higher number of X-Gal-positive cells in the SVZ.
Scale bar: 500 µm (A-G), 100 µm (H-N).
213
RESOURCE ARTICLE Disease Models & Mechanisms (2016) 9, 211-220 doi:10.1242/dmm.022715
D
is
ea
se
M
o
d
el
s
&
M
ec
h
an
is
m
s
a population of GFAP- and nestin-expressing cells in the SVZ
showed colocalisation with β-galactosidase, indicating that
the stem/progenitor cells, corresponding to B-type SVZ
cells (Doetsch et al., 1999), underwent recombination with
both methods.
Recombination of GLAST::Cre-expressing SVZ stem/
progenitor cells
Next, we sought to confirm that the cells that underwent
recombination corresponded functionally and biologically to
stem/progenitor cells, and were capable of forming neurospheres.
Stem and progenitor cells from the SVZ can be cultured in vitro as
neurospheres (Doetsch et al., 1999; Jacques et al., 1998, 2010; Lee
et al., 2005; Soares and Sotelo, 2004). GLAST::Cre(ERT);
ROSA26loxP/loxP mice were injected intraventricularly with 5 µl
5 mM endoxifen, and mice injected with 4 µl Adeno-Cre virus
[109 plaque-forming units (pfu)] served as positive control. At
7-10 days after ICV injection, mice were sacrificed and the SVZ
dissected to isolate and derive stem and progenitor cells as described
previously (Jacques et al., 1998). These stem/progenitor cells were
then cultured in permissive medium (Jacques et al., 1998) to form
neurospheres and assayed for recombination. In vivo recombination
of neurogenic SVZ cells is thought to give rise to a clonally
expanding population of recombined stem cells into a neurosphere,
which can be quantified in vitro (Fig. 4J-L). We found in our
unpassaged in vitro preparations derived from endoxifen-injected
GLAST::CreERT2;ROSA26loxP/loxPmice that 1.9% of neurospheres
showed recombination, compared to a higher rate of 4.3% of
neurospheres in Adeno-Cre-recombined ROSA26loxP/loxP mice
(Table 2).
Endoxifen-mediated recombination of the tumour
suppressor genes PTEN and p53 gives rise to brain tumours
We have previously shown that Adeno-Cre- or Adeno-GFAP-Cre-
induced recombination of the tumour suppressor genes Pten and
p53 in stem/progenitor cells of the SVZ gives rise to glial tumours,
with histological features of oligodendroglial and astrocytic
tumours (Henriquez et al., 2013). Here, we tested whether the
recombination of B-type stem/progenitor cells, using GLAST::
CreERT2 mice to recombine the tumour suppressor genes Pten and
p53 (GLAST::CreERT2;PtenloxP/loxP;p53loxP/loxP) would give rise
to similar tumours. IVC injection of 25 nmol endoxifen in 5 µl
volume generated tumours in three out of 16 injected mice.
Histological analysis showed lesions of different sizes and with
varying extents of infiltration. There were small neoplastic lesions
arising from beneath the SVZ, extending into the striatum and
dorsally into the corpus callosum. Larger tumours showed an
expansion into and a diffuse infiltration of the entire caudate
nucleus, and occasionally also infiltrated transcallosally into the
contralateral hemisphere (Fig. 5). Histologically, the tumours
showed a glial morphology with a range of features typical of
astrocytomas and oligodendrogliomas (Fig. 5B,D). Up to 20
mitoses/10 high-power fields were observed, and some of the
tumours contained areas of necrosis and occasional microvascular
proliferations, similar to those in malignant gliomas in humans and
similar to tumours generated by Adeno-Cre injection (Jacques et al.,
2010). Endoxifen-induced tumours expressed GFAP, nestin, Sox2,
Olig2, PDGFRa and doublecortin (Fig. 5E1-J1), and were
indistinguishable from tumours generated by Adeno-Cre or
Adeno-GFAP-Cre injection, as described previously (Henriquez
et al., 2013; Jacques et al., 2010) and as shown in Fig. 5E2-J3. There
was no expression of neuronal markers such as synaptophysin or
NeuN in all three models (Fig. 5K,L). Homozygous recombination
of both tumour suppressor genes was confirmed by microdissecting
tumours (Fig. 6A,B) and by recombination PCR of floxed p53
Fig. 3. Immunohistochemical detection of β-galactosidase expression in
the brain of endoxifen-injected GLAST::CreERT2;ROSA26loxP/loxP or in
Adeno-Cre-injected ROSA26loxP/loxP reporter mice. Left column:
expression of β-galactosidase in clusters of cells in the SVZ of the lateral
ventricles (A,D), and in ependymal cells (G) of the third ventricle. Arrowhead in
A points to a recombined cluster of cells. Cells of the choroid plexus (J) are not
recombined: they do not express GLAST in this mouse. Insert in G shows
recombined cells in the ependymal layer. Middle column: upon Adeno-Cre-
mediated recombination, there is widespread expression of β-galactosidase in
the cells of the SVZ (B,E), and ependymal cells of the third ventricle (H). Also, a
population of choroid plexus cells (K) underwent recombination and expressed
β-galactosidase. Right column: no recombination is seen in controls, which
were injected with PBS. (M-O)Widespread expression in the brain is seen after
intraperitoneal application of tamoxifen, including in astrocytes in the cortex (N;
higher-magnification view of the uppermost box in M) and deep beneath the
SVZ (O; higher-magnification view of the lowermost box in M). Scale bar:
50 µm (A-C,N,O), 100 µm (D-L), 1.8 mm (M).
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alleles (Fig. 6C,D), whereas homozygous recombination of the
floxed PTEN alleles was assessed by the expression of pAkt
(Fig. 6E,G), which becomes phosphorylated upon loss of function
of both copies of PTEN, as described previously (Groszer et al.,
2001; Kwon et al., 2001; Marino et al., 2002).
DISCUSSION
We present here a method that allows for a cell-type-specific
recombination, in a defined region of the brain, and validate its use
to study the pathobiology of disease in a brain tumour model.
Several different methods have been developed to achieve Cre-
mediated recombination. Targeted gene inactivation often causes
embryonic lethality, for example in knockout mice for Rb (Jacks
et al., 1992), Apc (Su et al., 1992) orPten (Di Cristofano et al., 1998;
Stambolic et al., 1998; Suzuki et al., 1998). Subsequently, Cre-
mediated inducible gene inactivation, combined with mice carrying
loxP recognition sequences (Gu et al., 1994, 1993; Kuhn et al.,
1995), was developed to circumvent embryonic lethality by
targeting specific cell types or regions. Several possibilities exist
to achieve the expression of Cre recombinase in a chosen cell type.
Most commonly, a separate mouse line is generated that expresses
Cre recombinase under the control of a cell- or tissue-specific
promoter. An important caveat, essential for the correct
interpretation of a phenotype, is that recombination begins once
theCre transgene becomes activated. During brain development, for
example, many promoters, such as nestin, GFAP or engrailed-2
are transiently expressed in neural precursor/progenitor cell
populations, resulting in a permanent deletion of the target gene,
regardless of the fate of their progeny (Backman et al., 2001; Kwon
et al., 2001; Marino et al., 2002, 2000). Topical application of Cre
recombinase, for example using an adenoviral vector (Ahmed et al.,
2004; Anton and Graham, 1995; Kaspar et al., 2002; Wang et al.,
2006), is a successful approach to achieve recombination of GFAP-
or nestin-expressing cells of the SVZ. Administered into the
ventricles, the virus infects stem and progenitor cells of the SVZ,
and also a few other cell types, such as choroid plexus epithelial
cells. In the parenchyma, it recombines mature astrocytes and
neurons (Jacques et al., 2010). A more selective expression in
astrocytes was achieved by an adenovirus that expressed Cre under
the control of the GFAP promoter (Jacques et al., 2010; Mirzadeh
et al., 2008) (Fig. 5), but this reduced efficacy in eliciting brain
Fig. 4. Expression of Cre recombinase, and
characterisation of recombined cells. (A-C) Double-
labelling immunofluorescence detects cells expressing Cre
recombinase following endoxifen administration in GLAST::
CreERT2;ROSA26loxP/loxP reporter mice (A) or following
Adeno-Cre-mediated recombination in ROSA26loxP/loxP
reporter mice (B). Co-expression of GFAP and Cre
recombinase appears yellow. Arrowheads indicate cells
expressing both antigens. (D-I) Recombination of (D-F)
GFAP-expressing and (G-I) nestin-expressing cells in the
SVZ indicates effective endoxifen-mediated recombination in
GLAST::CreERT2;ROSA26loxP/loxP reporter mice and
confirms targeting of GFAP- and nestin-expressing
progenitors. Arrowheads indicate cells expressing both
antigens. No Cre expression and recombination was
observed in controls (C,F,I). (J-L) Stem/progenitor cells of the
SVZ give rise to neurospheres when cultured in permissive
medium. Stem/progenitor cells that underwent recombination
in vivo by intraventricular injection of endoxifen (J) or Adeno-
Cre (K) give rise to recombined, β-galactosidase-expressing,
progenies, which form blue spheres in the X-Gal assay. No
recombination was observed in controls (L). Scale bar: 50 µm
(A-I), 300 µm (J-L).
Table 2. Recombination rate of SVZ stem/progenitor cells in the
neurosphere assay
β-gal pos. Total (pos.+neg.) % pos.
Negative control #1 0 106 0.0
Negative control #2 0 180 0.0
Endoxifen #1 6 243 2.5
Endoxifen #2 17 219 7.8
Endoxifen #3 3 74 4.1
Endoxifen #4 2 172 1.2
Adeno-Cre 12 155 7.7
Number of β-galactosidase-positive (pos.) neurospheres in the total
population of SVZ-derived neurospheres. No recombination was observed in
the negative controls, and a variable range of recombination efficiency
occurred in GLAST::CreERT2;ROSA26loxP/loxP mice injected
intraventricularly with 5 µl 5 mM (25 nmol) endoxifen. At least threemicewere
pooled per experiment to derive neurospheres. neg., negative.
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tumours. An alternative approach is the use of tamoxifen-inducible
Cre expression in the brain, for example GFAP::CreERT or nestin::
CreERT2 (Chow et al., 2011). Recombination in the CreERT2
system is usually accomplished by intraperitoneal injection of
tamoxifen, which is metabolised in the liver into metabolites that
have a higher affinity to the mutated ER. Fused with Cre
recombinase (Guo et al., 2002), this receptor is used in most
ERT2 models, including the GLAST::CreERT2 mouse. Systemic
tamoxifen application, however, causes widespread additional
recombination of astrocytes and Müller cells (Mori et al., 2006)
(Fig. 3M-O). Instead, endoxifen, with its higher affinity to the
mutated ER, injected into the ventricle of GLAST::CreERT2 mice
(Hayashi and McMahon, 2002; Lim et al., 2006; Stearns et al.,
2003), restricted recombination to SVZ cells, likely to represent
stem/progenitor cells (Figs 4A,D,G and 3A,D,G).
The limitations of this method are the toxicity of tamoxifen
derivatives and thus the relatively smaller number cells that undergo
recombination when using smaller dosages. Injection of 5 µl 25 mM
endoxifen (125 nmol), dissolved in DMSO, caused a proportion of
mice to exhibit neurological signs including seizures after a latency of
2-6 hours, requiring them to be culled. This toxicity is unlikely to be
caused by DMSO because its injection as vehicle only did not cause
side effects and showed no increased cell death (Fig. 1A,B). Reduction
to 5 mM endoxifen concentration (dose 25 nmol) was tolerated well.
However, recombination efficiency was correspondingly reduced
(Fig. 2). This suggests that Cre-mediated recombination is a stochastic
process, which has implications for tumorigenesis.
The objective to develop this model was to refine targeting of stem/
progenitor cells using a cell-specific promoter (Mori et al., 2006) and
an established combination of tumour suppressor genes, known to
generate gliomas (Chow et al., 2011; Henriquez et al., 2013; Jacques
et al., 2010; Zheng et al., 2008; Zhu et al., 2005). Here we compared
an established, robust glioma model (Adeno-Cre-mediated
recombination of PtenloxP/loxP/p53loxP/loxP in the SVZ), with that
Fig. 5. Formation of gliomas. The formation of gliomas was assessed in endoxifen-injectedGLAST::CreERT2;p53loxP/loxP;PtenloxP/loxPmice (columns 1, 4), and
in Adeno-Cre-injected (columns 2, 5) or Adeno-GFAP-Cre-injected p53loxP/loxP;PtenloxP/loxPmice (columns 3, 6). (A,C) Overviewof coronal sections on the level of
the SVZ. The boxes indicate the areas shown at higher magnification in B and D, showing a diffusely infiltrating glioma in the lateral corner of the ventricle.
CC, corpus callosum; LV, lateral ventricle; HC, hippocampus. (C,D) Posterior level of the same brain as in A and B, showing an infiltrative tumour arising from the
ventricle. The boxed areas in D indicate the areas shown in I-L. (E-L) Immunohistochemical analysis of the same brains, from the anterior level (A,B) or posterior
level (C,D). Tumours elicited by the threemethods show similar expression patterns, all consistent with gliomas. (E) Tumours express GFAP (note that underlying
brain astrocytes also contribute to the GFAP-positive population). (F) Expression of nestin by tumour cell processes. (G-J) Strong expression of doublecortin (G),
PDGFRα (H) and themarkers Olig2 (I) and Sox2 (J). (K,L) None of the tumours express neuronalmarkers: synaptophysin (K) and NeuN (L) are negative in tumour
cells, whereas they are expressed by surrounding brain tissue or in scattered entrapped neurones (L1). Scale bar: 4 mm (A,C), 500 µm (B,D) and 200 µm (E-L).
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of endoxifen induced GLAST::Cre-mediated recombination of
PtenloxP/loxP/p53loxP/loxP. The tumour incidence after endoxifen-
induced recombination (3 of 13; 23%), was however similar to
that in Adeno-Cre-induced mice (16 of 47; 34%) (P=0.52; Fisher’s
exact test) (Table 3). Tumours generated with all three approaches
were histologically indistinguishable (Fig. 5), with a spectrum of
astrocytic and oligodendroglial tumour features, similar to the
variability in human tumours (Brandner and von Deimling,
2015), consistent with our previous findings (Henriquez et al.,
2013; Jacques et al., 2010).
The target of Adeno-Cre is not precisely defined, and likely
includes B-type stem cells and (at least a proportion of) C-type
transient amplifying cells (Jacques et al., 2010), whereas
recombination in the GLAST::CreERT2 model is better defined,
affecting chiefly B-type SVZ cells (Mori et al., 2006). The overall
incidence of brain tumours does not show significant differences
between the two models possibly because a recombination event
in a restricted population (for example, B-type cells) will still
give rise to progenies of these cells, and ultimately leads to a
wider range of recombined progenies sufficient to form a brain
tumour at a frequency that is comparable with that achieved
with Adeno-Cre-mediated recombination (Fig. 7). However,
there is a difference in latencies between these two models. To
exclude that this was caused by incomplete recombination in the
endoxifen model, we confirmed recombination of both alleles.
Recombination-specific PCR (Marino et al., 2000) confirms that
both p53loxP/loxP alleles underwent recombination (Fig. 6C,D) and,
by detection of pAkt expression, that both PTEN alleles were
recombined (Fig. 6E-H). Recombination of a single PTEN
allele does not result in detectable pAkt expression (Marino et al.,
2002), owing to the haplosufficiency of PTEN. Importantly,
all three models, Adeno-Cre, Adeno-GFAP-Cre and endoxifen-
inducedGLAST::CreERT2-mediated recombination, elicit the same
type of tumours, i.e. a range of astrocytic and oligodendroglial
tumours with indistinguishable immunoprofiles (Fig. 6E-L).
In conclusion, we have established and validated a novel approach
to recombine a regionally defined cell population using direct
application of the tamoxifen metabolite endoxifen in the CNS and
we demonstrate its usefulness for specific biological questions, in
that endoxifen-induced GLAST::CreERT2 mediated recombination
of tumour suppressor genes results in the formation of brain
tumours.
MATERIALS AND METHODS
Transgenic mice
Combinations of the conditional mousemutants p53loxP/loxP andPtenloxP/loxP
(Marino et al., 2002, 2000) all in a ROSA26loxP/loxP background (Soriano,
1999) were used as described before (Henriquez et al., 2013; Jacques et al.,
2010).GLAST::CreERT2micewere obtained fromM.Goetz,Munich (Mori
et al., 2006). Animals were kept according to institutional and UK Home
Office guidelines (project licences 70/5540 and 70/6603). The ARRIVE
guidelines were followed as part of the institutional policy and the licensing
of the experiments.
Intraperitoneal injection of tamoxifen
Animals were injected with 0.1 ml of 20 mg/ml tamoxifen each day for
5 days. Tamoxifen injectable solution was prepared with tamoxifen Free
Base (Sigma T5648), ethanol and corn oil (Sigma C8267), as previously
published (Lau et al., 2011; Madisen et al., 2010).
Stereotaxic injection of adenovirus and tamoxifen metabolites
The Cre adenovirus vector was constructed and propagated as described
(Akagi et al., 1997). Viral infection of SVZ progenitors was achieved by
Fig. 6. Detection of gene recombination in endoxifen- or Adeno-Cre-
induced tumours. (A,B) Microdissection of tumours. Tumours correspond to
T1 (A) and T2 (B) (see C). (A,B) Prior to microdissection; (A′,B′) after
microdissection. (C) Recombination PCR showing a 612-bp band (blue
arrowhead) in recombined tumour tissue (T1, T2) but not in wild-type (wt) brain,
or non-recombined brain tissue of naïve GLAST::Cre(ERT2);PtenloxP/loxP;
p53loxP/loxPmice (lox nr); NT, non-template control; RC, in vitro-recombined cell
line derived from the SVZ of a PtenloxP/loxP;p53loxP/loxP mouse. (D) PCR
detecting wild-type and non-recombined DNA only. A 512-bp band (red
arrowheads) is seen only in non-recombined (lox nr) brain but not in
recombined tumour (T1, T2). A 400-bp wild-type is seen in non-transgenic
controls only. No signal is detected in the non-template control (NT)
or in recombined in vitro-recombined cell line derived from the SVZ of a
PtenloxP/loxP;p53loxP/loxP mouse. (E-H) Homozygous PtenloxP/loxP
recombination (exon 5) leads to loss of functional PTEN protein and results
in upregulation of pAkt (brown immunolabelling). (E,G) Tumour cells that
undergo recombination of both alleles express detectable amounts of pAkt,
whereas adjacent CNS tissue does not express pAkt (F,H). Scale bar: 100 µm
in E-H.
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unilateral stereotaxic injections of 109 pfu of adenovirus expressing Cre
recombinase (in short Adeno-Cre) with a 26 G needle attached to a 10 µl
gastight Hamilton syringe (model 1701 RN#80030) in 5 µl PBS into the left
ventricle of compound mutant mice as described and characterised in detail
previously (Jacques et al., 2010).
Tamoxifen was injected as active metabolite 4-hydroxytamoxifen
(4-OH-TAM, SIGMA H7904) (Jordan, 2007), or 4-hydroxy-N-
desmethyltamoxifen (endoxifen, Sigma E8284) (Ahmad et al., 2010;
Johnson et al., 2004; Jordan, 2007; Stearns et al., 2003). 4-OH-TAM was
dissolved at 1 mM concentration in 2% ethanol/PBS and 5 µl injected into the
ventricles. Endoxifen had not been used before for the induction of the ERT2
system in vivo. Endoxifen hydrochloride hydrate (Sigma E8284) has a
recommended solubility of over 10 mg/ml (∼25 mM) in 100% DMSO,
corresponding to a maximum concentration of 25 mM or a dose of 125 nmol
in a 5 µl volume. At this concentration, a proportion of mice developed
neurological signs suggestive of neurotoxicity and had to be culled (see
Results and Table 1). Subsequently, concentrations of 2.5, 5, 10, 12.5 and
25 mM, dissolved in 10, 20, 40, 50 and 100% DMSO, respectively,
corresponding to a drug dose of 12.5, 25, 50, 62.5 and 125 nmol were used.
For testing DMSO toxicity, groups of three mice were injected with 5 µl PBS,
50% DMSO in PBS or 100% DMSO in PBS. Mice were culled 9 days after
injection and coronally sectioned brains were stained for cleaved caspase 3,
GFAP and Iba1.
Isolation, propagation and staining of neurospheres
Neurospheres were isolated from young adult mouse brains and propagated
in serum-free medium based on DMEM/HamF12 (#D8437, Sigma), and
supplemented with B27 (1:50; #17504-044, Invitrogen), EGF (20 ng/ml;
#315-09, PeproTech), bFGF (20 ng/ml; #100-18B, PeproTech), as
described previously (Jacques et al., 2010). For X-Gal enzymatic staining,
neurospheres were transferred from the 10 cm dish into a four-well plate
(well diameter 10 mm) with 150 µl growth medium, and incubated for
30 min in staining buffer that was composed of: 10 mM phosphate buffer,
150 mM NaCl, 1 mM MgCl2, 3.3 mM K4Fe(CN)6×3H2O, 3.3 mM
K3Fe(CN)6, 1% MgCl2, 0.02% IGEPAL and 0.01% sodium deoxycholate
and 1% X-Gal. Spheres were photographed through a Stemi SV11 (Zeiss)
stereomicroscope, and counted using ImageJ.
Histological examination and immunostaining
Mice that developed clinical signs of intracranial pressure were culled, and
brain removed and fixed in 10% formalin, embedded in paraffin, cut to 3-µm
sections and stained with haematoxylin-eosin (H&E). Immunostaining was
done on Ventana Discovery automated staining machines (ROCHE, Burgess
Hill, UK) following the manufacturer’s guidelines, using horseradish-
peroxidase-conjugated streptavidin complex and diaminobenzidine as a
chromogen. The following antibodies were used for histological
characterisation: anti-GFAP (DAKO Z0334, 1:1000), -NeuN (Chemicon
MAB377, 1:1000), -nestin (Abcam ab11306, 1:400), -synaptophysin (Zymed
080130, prediluted), -Sox2 (Millipore AB5603, 1:100), -doublecortin
(Abcam AB18723, 1:100), -Olig2 (Millipore AB9610, 1:100), -PDGFRα
(Abcam ab15501, prediluted preparation), rabbit anti-β-galactosidase
(Chemicon AB1211, 1:250), rabbit anti-Cre-recombinase (Covance
PRB1061C, 1:500), anti-cleaved caspase-3 (Asp175) (Cell Signaling
#9661); anti-phospho-Akt (Ser473) (D9E), and rabbit mAb (Cell Signaling
#4060). Counterstain of fluorescent sections was donewith 4′,6-diamidino-2-
phenylindole, dihydrochloride (DAPI) (Life Technologies D1306).
For immunofluorescent antigen detection, cryostat sections of 14-µm
thickness were prepared from perfusion-fixed, coronally oriented brains,
and mounted on Superfrost Slides. Fluorescence-labelled secondary
antibodies from molecular probes (Alexa Fluor 488, Alexa Fluor 546)
were used for detection.
Tissue microdissection, DNA extraction from paraffin sections
and recombination PCR
PCR analysis of Cre-mediated recombination was performed on genomic
DNA extracted from tumours microdissected from paraffin sections. DNA
extracted from the cerebellum of an En2cre; p53loxP/loxP and PtenloxP/loxP
mouse (similar to those described in Marino et al., 2002) and a cell line
derived from in vitro recombined SVZ stem/progenitor cells of a p53loxP/loxP
and PtenloxP/loxP mouse as described in Jacques et al. (2010) served as
positive control.
MasterPure Complete DNA & RNA Purification Kit (Epicentre,
Illumina) was used for extraction of DNA. Paraffin sections were de-
waxed with xylene, followed by ethanol and air-dried. Microdissected tissue
was digested with 4 μl proteinase K (50 μg/μl) in 300 μl of Lysis Solution
Fig. 7. Latency and frequency of tumour
formation after Cre-mediated
recombination. The x-axis represents the
latency in days and each circle represents
an individual tumour. Half-filled circles
represent precursor lesions. Mice that died
prematurely or were culled owing to
unrelated health concerns at 20-50 days of
incubation were excluded from analysis,
because tumour development does not
occur before 100 days.
Table 3. Comparison of tumorigenesis induced by endoxifen-mediated Cre recombination in GLAST::CreERT2;p53loxP/loxP;PtenloxP/loxP mice and
Adeno-Cre-injected p53loxP/loxP;PtenloxP/loxP mice
Recombination
method Genotype
Sample
size Microneoplasia
Microneoplasia
incidence (%)
Intrinsic
tumours
Total incidence of
lesions (%)
Tumour
incidence (%)
Adeno-Cre p53loxP/loxP;PtenloxP/loxP 51 5 9.8 17 45.1 33.3
Endoxifen,
25 nmol
GLAST::CreERT2;
p53loxP/loxP;
PtenloxP/loxP
16 4 25.0 3 43.8 18.8
Only mice developing glial neoplasms were included in the Adeno-Cre group. Other tumours were observed, as described in Jacques et al. (2010). All
microneoplastic lesions (tumour precursors) and fully developed tumours in the endoxifen groups were histologically gliomas.
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and subsequent steps were carried out according to the manufacturer’s
instructions.
Reactions contained 30 ng of template DNA, 0.5 μm primers, 250 μm
dNTPs, 9% glycerol, 2.5 units of FastStart Taq DNA polymerase (Roche)
and 1× FastStart Taq PCR reaction buffer with 2 mM MgCl2 in a 50 μl
volume. Thermocycling conditions consisted of 35 cycles of 30 s at 95°C,
60 s at 58°C, and 60 s at 72°C. p53 recombination was assayed with primers
5′-CACAAAAACAGGTTAAACCCA-3′ (p53-int1-fwd) and 5′-GAAGA-
CAGAAAAGGGGAGGG-3′ (p53-int10-rev) yielding a 612-bp product.
The presence of the unrecombined p53 floxed gene was assayed with
primers 5′-AAGGGGTATGAGGGACAAGG-3′ (p53-int 10-fwd) and
5′-GAAGACAGAAAAGGGGAGGG-3′ (p53-int 10-rev) yielding a
584-bp product (unrecombined floxed p53 allele) and/or 400-bp product
(wild-type p53 allele) (Marino et al., 2000).
Image capturing and analysis
Histological slides were digitised on a LEICA SCN400 scanner (LEICA
UK) at 40× magnification and 65% image compression setting, and images
were stored on Slidepath Digital Image Hub (Leica Microsystems).
Fluorescent images were acquired on a ZEISS LSM710 META confocal
laser scanning microscope and processed with the ZEN software.
X-Gal-stained frozen sections were captured prior to counterstaining on
an Olympus MegaView III digital camera, attached to a Zeiss Axioskop and
then counterstained with Nuclear Fast Red, and images were digitised on a
LECIA SCN400 scanner.
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